• Home
  •  / AstraZeneca

AstraZeneca

OverviewSuggest Edit

AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. It develops drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology. The company offers its products to primary care and specialty care physicians through distributors and local representative offices.

TypePublic
Founded1999
HQCambridge, GBMap
Websiteastrazeneca.com
Employee Ratings4.1More
Overall CultureB+More
View Jobs (2,808)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)76,100(+8%)
Job Openings2,808
Revenue (FY, 2021)$37.4 B(+41%)
Share Price (Apr 2022)£105.1(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Johan Hyllner

Johan Hyllner

Senior Director and Head of Cell Therapy, BioPharmaceuticals R&D
J P Morgan

J P Morgan

Virtual Conference, , European Healthcare CEO Series [Management]
Katarina Ageborg

Katarina Ageborg

Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca Sweden
Pam Cheng

Pam Cheng

Executive Vice-President, Operations and Information Technology
Ruud Dobber

Ruud Dobber

Executive Vice-President, BioPharmaceuticals Business Unit
Show more

AstraZeneca Office Locations

AstraZeneca has offices in Cambridge, Harlow, London, Luton and in 100 other locations
Cambridge, GB (HQ)
1 Francis Crick Ave
Cambridge, GB
136 Hills Rd
Harlow, GB
Lovet Rd
London, GB
15 Stanhope Gate
London, GB
2 Kingdom St
Luton, GB
600 Capability Green
Show all (112)

AstraZeneca Financials and Metrics

AstraZeneca Revenue

AstraZeneca's revenue was reported to be $37.42 b in FY, 2021
USD

Revenue (FY, 2021)

37.4b

Gross profit (FY, 2021)

33.0b

Net income (FY, 2021)

115.0m

EBITDA (FY, 2021)

7.0b

EBIT (FY, 2021)

992.0m

Market capitalization (27-Apr-2022)

162.9b

Closing stock price (27-Apr-2022)

105.1

Cash (31-Dec-2021)

6.3b

EV

187.3b
AstraZeneca's current market capitalization is £162.9 b.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

22.1b24.4b26.6b37.4b

Cost of goods sold

(1.2b)(1.2b)(2.2b)(5.9b)

Gross profit

21.7b23.7b25.0b33.0b

R&D expense

(5.9b)(6.1b)(6.0b)(9.7b)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

5.5b5.8b6.4b6.4b6.3b6.6b7.3b8.2b9.9b

Cost of goods sold

(453.0m)(336.0m)(635.0m)(579.0m)(274.0m)(569.0m)(1.1b)(1.4b)(969.0m)

Gross profit

5.6b5.6b6.1b6.3b6.1b6.3b7.4b6.9b8.9b

R&D expense

(1.3b)(1.4b)(1.3b)(1.4b)(1.4b)(1.5b)(1.7b)(1.8b)(3.6b)
show all
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

4.8b5.4b7.8b6.3b

Accounts Receivable

3.0b3.6b3.8b9.6b

Prepaid Expenses

1.6b1.2b2.1b663.0m

Inventories

2.9b3.2b4.0b9.0b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

4.1b5.4b4.0b3.4b5.7b8.1b7.6b15.6b7.1b

Accounts Receivable

5.3b5.3b5.3b5.1b5.0b5.7b6.3b6.4b8.3b

Prepaid Expenses

118.0m246.0m228.0m262.0m213.0m332.0m347.0m486.0m596.0m

Inventories

3.1b3.2b3.1b3.1b3.6b3.7b4.3b4.8b10.5b
show all
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

2.0b1.5b3.9b(265.0m)

Depreciation and Amortization

3.8b3.8b3.1b6.5b

Inventories

(13.0m)(316.0m)(621.0m)

Accounts Payable

(103.0m)868.0m1.7b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

758.0m899.0m1.3b935.0m1.9b2.7b1.6b2.4b371.0m

Depreciation and Amortization

676.0m1.4b2.1b841.0m1.6b2.4b797.0m1.6b4.3b
show all
USDFY, 2018

EV/EBITDA

21.5 x

EV/EBIT

33.8 x

EV/CFO

42.2 x

Revenue/Employee

342.0k
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Projects in R&D Pipeline

99133146132144149167171

Phase I Trials Projects

3324444150383435

Phase II Trials Projects

2711333637435042

Phase III Trials Projects

1911352723222725
Show all operating metrics

AstraZeneca Acquisitions / Subsidiaries

Company NameDateDeal Size
Alexion PharmaceuticalsDecember 12, 2020$39 b
Takeda Respiratory BusinessMay 10, 2016$575 m
AcertaPharmaDecember 17, 2015$4 b
ZS PharmaNovember 06, 2015$2.7 b
AlmirallJuly 30, 2014
Pearl TherapeuticsJune 10, 2013$1.2 b
Omthera PharmaceuticalsMay 29, 2013$323 m
Ardea BiosciencesApril 23, 2012$781 m
Guangdong BeiKang Pharmaceutical Company LtdDecember 08, 2011
NovexelDecember 23, 2009
Show more

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 34.9% from ONCOLOGY, 6.3% from OTHER MEDICINES, 10.7% from COVID-19, 21.4% from BIOPHARMACEUTICALS: CVRM, 16.1% from BIOPHARMACEUTICALS: R&I, 8.2% from RARE DISEASE and 2.3% from Other

Human Capital Metrics

Source: www.astrazeneca.com
Embed Graph
Show all human capital metrics

AstraZeneca Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

Learn more about our premium products
SecurityScorecard logo

AstraZeneca Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

AstraZeneca Online and Social Media Presence

AstraZeneca's Trends

Embed Graph

AstraZeneca Company Culture

  • Overall Culture

    B+

    73/100

  • CEO Rating

    A-

    76/100

  • Compensation

    A-

    77/100

  • Diversity

    C+

    67/100

Learn more on Comparably

AstraZeneca News and Updates

April 29, 2022

Global Artificial Coma/Medically Induced Coma Market Report 2022, Featuring Profiles of Astrazeneca, Baxter Healthcare, Dr. Reddy's Laboratories, Fresenius and Piramal Healthcare

Dublin, April 29, 2022 (GLOBE NEWSWIRE) -- The "Global Artificial Coma/Medically Induced Coma Market Opportunity Analysis and Industry Forecast (by Drug Type, Application and Distribution Channel), 2021-2030" report has been added to ResearchAndMarkets.com's offering. The global artificial coma/me…
April 18, 2022

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasdaq: AZN), a global, sci…
April 07, 2022

Worldwide Cancer Immunotherapy Industry to 2027 - Featuring Amgen, AstraZeneca and Bayer Among Others

Dublin, April 07, 2022 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global cancer immunotherapy market reached a value of US$ 96.6 Billion in 20…
April 04, 2022

Worldwide Antibody Cocktails Industry to 2028 - Featuring Cipla, Regeneron Pharmaceuticals and AstraZeneca Among Others

Dublin, April 04, 2022 (GLOBE NEWSWIRE) -- The "Antibody Cocktails Market, by Type, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. An antibody, also called immunoglobul…
March 23, 2022

AstraZeneca takes stake in a start-up that helps doctors conduct clinical trials virtually

AstraZeneca has taken a roughly £25 million ($33 million) stake in U.K. health start-up Huma, according to a person familiar with the matter.
March 23, 2022

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

LONDON and NEW YORK, March 23, 2022 /PRNewswire/ -- Huma Therapeutics Limited, a global digital health technology company advancing digital-first care delivery and research to help people live longer, fuller lives, today announced a new partnership with AstraZeneca to scale innovation for...
Show more

AstraZeneca Blogs

May 17, 2022

AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19

May 15, 2022

PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma

May 12, 2022

Human ventricular progenitor cells promote the formation of new heart tissue following a heart attack

May 05, 2022

Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

May 05, 2022

Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

May 05, 2022

Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder

Show more

 AstraZeneca Frequently Asked Questions

  • When was AstraZeneca founded?

    AstraZeneca was founded in 1999.

  • Who are AstraZeneca key executives?

    AstraZeneca's key executives are Pascal Soriot, Johan Hyllner and J P Morgan.

  • How many employees does AstraZeneca have?

    AstraZeneca has 76,100 employees.

  • What is AstraZeneca revenue?

    Latest AstraZeneca annual revenue is $37.4 b.

  • What is AstraZeneca revenue per employee?

    Latest AstraZeneca revenue per employee is $491.7 k.

  • Who are AstraZeneca competitors?

    Competitors of AstraZeneca include Daiichi Sankyo, Boehringer Ingelheim and Sanofi.

  • Where is AstraZeneca headquarters?

    AstraZeneca headquarters is located at 1 Francis Crick Ave, Cambridge.

  • Where are AstraZeneca offices?

    AstraZeneca has offices in Cambridge, Harlow, London, Luton and in 100 other locations.

  • How many offices does AstraZeneca have?

    AstraZeneca has 112 offices.